Diagnostic Products Aided By HBV Assay Approval; Q3 Index Composite Flat
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic Products Corp.'s foray into the U.S. hepatitis B immunoassay market, continued strong Immulite sales and a favorable public policy environment helped push the firm's stock ahead 24.3% in the third quarter